研究美敦力780G胰岛素泵在胃轻瘫合并1型糖尿病患者中的疗效与安全性。
美敦力780G自动胰岛素输送系统在患有1型糖尿病和胃轻瘫的成人中的疗效与安全性
The goal of this clinical trial is to evaluate the efficacy and safety of Medtronic 780G automated insulin delivery system in adult persons with type 1 diabetes and gastroparesis.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Sana Kalaji
- 电话号码:317-278-6017
- 邮箱:skalaji@iu.edu
学习地点
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Indiana University Health, Univeristy hospital
-
首席研究员:
- Viral Shah, MD
-
接触:
- Zunera Tariq, MD
- 电话号码:317-278-0907
- 邮箱:tariqz@iu.edu
-
接触:
- Viral Shah, MD
- 电话号码:317-278-6017
- 邮箱:tariqz@iu.edu
-
副研究员:
- Zunera Tariq, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria
- Age ≥18 years
- Diagnosis of T1D for at least 12 months with stable insulin regimen for at least 2 months
- HbA1c ≥8.0%
- Diagnosis of gastroparesis per National Institute of Health (NIH) definition
- Willing to use Medtronic 780G system either with Simplera CGM.
- Ability to provide informed consent before any trial-related activities
- If randomized to usual care group and on an insulin pump already, should be willing to use pump in manual mode only for the duration of the study
Exclusion criteria
- Age <18 years
- Current use of inhaled insulin (Afrezza)
- Patients with T1D using any glucose lowering medications other than insulin at the time of screening
- Pregnancy, breast feeding, or wanting to become pregnant
- Current use (≥ 2 weeks of continuous use) of any steroidal medication, or anticipated long-term steroidal treatment (>4 weeks continuously), during the study period
- History of gastric outlet obstruction or other gastrointestinal structural abnormalities
- Estimated glomerular filtration rate (eGFR) <30 or on dialysis
- History of SH in the previous 3 months
- History of two or more episodes DKA requiring hospitalization in the past 12 months
- Any medical (such as severe cardiovascular disease, malignancy, chronic liver disease) or psychosocial conditions that make a person unfit for the study at the discretion of investigators
- Use of investigational drugs within 5 half-lives prior to screening
- Current use of cannabis or history of cannabinoid hyperemesis syndrome
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Medtronic 780G 组
|
Participants in Medtronic AID treatment group will use it for three months |
|
无干预:Usual care
Participants will continue either multiple daily injections or non-AID insulin pumps |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time in Range (70-180 mg/dL)
大体时间:Baseline to 3 months
|
Percentage of time that sensor glucose values are within the target range of 70-180 mg/dL, as measured by continuous glucose monitoring (CGM). |
Baseline to 3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
HbA1c
大体时间:Baseline to 3 months
|
Change in glycated hemoglobin (HbA1c) measured using standard laboratory methods. |
Baseline to 3 months
|
|
Mean Sensor Glucose
大体时间:Baseline to 3 months
|
Mean sensor glucose value derived from CGM data. |
Baseline to 3 months
|
|
Time in Tight Target Range (70-140 mg/dL)
大体时间:Baseline to 3 months
|
Percentage of time that sensor glucose values are between 70 and 140 mg/dL (TTIR), measured by CGM. |
Baseline to 3 months
|
|
Time Above Range
大体时间:Baseline to 3 months
|
Percentage of time that sensor glucose values are >180 mg/dL and >250 mg/dL, measured by CGM. |
Baseline to 3 months
|
|
Time Below Range
大体时间:Baseline to 3 months
|
Percentage of time that sensor glucose values are <70 mg/dL and <54 mg/dL, measured by CGM. |
Baseline to 3 months
|
|
Glucose Variability
大体时间:Baseline to 3 months
|
Glucose variability assessed by the standard deviation (SD) of sensor glucose values from CGM data. |
Baseline to 3 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Severe Hypoglycemia
大体时间:3 months
|
Number of severe hypoglycemic events requiring assistance from another person. |
3 months
|
|
Diabetic Ketoacidosis
大体时间:3 months
|
Number of diabetic ketoacidosis events defined by standard clinical criteria. |
3 months
|
合作者和调查者
合作者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 28244
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Will be shared in future
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.